Dianthus Therapeutics Reports Q3 GAAP EPS of -$0.81, Exceeding Estimates
Dianthus Therapeutics (NASDAQ: DNTH) reported third-quarter financial results, posting a GAAP earnings per share (EPS) of -$0.81. This figure outperformed market expectations by $0.18. The company also reported quarterly revenue of $1.21 million. While the company continues to operate at a loss, the earnings beat suggests better-than-anticipated cost management or operational efficiency during the period.
Tickers: $DNTH
Topics: earnings beat GAAP EPS revenue